Age-related Normative Values for the Octopus 900 Perimeter
NCT ID: NCT01518686
Last Updated: 2013-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
86 participants
INTERVENTIONAL
2006-06-30
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
one arm
observational study, no cohort, single group of different ages
Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)
We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .
The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)
We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .
The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* maximum cylindrical ametropia ± 2 D
* distant visual acuity ≥ 1.0 logMAR \[20/20\] for subjects up to 60 years, ≥ 0.8 logMAR \[20/25\] for subjects from 61-70 years, ≥ 0.63 logMAR \[20/30\] for subjects older than 70 years
* isocoria, pupil diameter \> 3mm
* intraocular pressure (air pulse tonometer) ≤ 21mmHg
* normal anterior segments
* ocular fundus: normal appearance of the cup to disc ratio (CDR) ≤ 0.5, interocular difference of CDR \< 0.3
* normal macular region, vessels, and peripheral retinal examination (with undilated pupils).
Exclusion Criteria
* strabismus
* ocular motility disorder
* diseases of the retina
* glaucoma, glaucoma suspect
* macular degeneration
* IOP \> 21 mmHg
* abnormal color vision test (ISPP - Ishihara and Standard Pseudoisochromatic Plates = SPP)
* history or findings of other neuro-ophthalmological disease
* relevant opacities of the central refractive media (cornea, lens, vitreous body)
* use of miotic drugs
* intraocular surgery (except uncomplicated cataract surgery, more than three months previous to testing)
* kerato-refractive surgery (LASIK)
* drugs influencing reaction time
* drugs indicating severe general diseases (anti-diabetic pharmaceuticals and anti-hypertensive medication were allowed for subjects older than 70 years)
* mental diseases (for example psychosis)
* pregnancy, nursing
* acute infections
* heavy smoking (\>10 cigarettes /day)
* alcohol abuse
* diabetic retinopathy
* coronary heart disease
* stroke
* migraine
* Raynaud's syndrome
* suspected lack of compliance
11 Years
79 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Haag-Streit AG
INDUSTRY
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ulrich Schiefer
Prof. Dr. med Ulrich Schiefer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ulrich Schiefer, Prof. Dr. med.
Role: PRINCIPAL_INVESTIGATOR
Centre for Ophthalmology / Institute for Ophthalmic Research, University of Tübingen, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for Ophthalmology / Institute for Ophthalmic Research, University of Tübingen
Tübingen, Baden-Wurttemberg, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
217/2006 local review board
Identifier Type: -
Identifier Source: org_study_id